MS Research Australia’s landmark PrevANZ vitamin D MS prevention trial is
continuing to make steady progress, and has reached the exciting milestone of
110 patients enrolled in the trial towards our target of 240 participants.
international MS research community continues to watch the trial with great
anticipation, as this trial will provide the much needed evidence as to whether
vitamin D supplementation can have a clinical benefit for people at high risk
Professor Bill Carroll, Chair of the PrevANZ Clinical Trial Steering
Committee said, “This study remains unique and the MS research community
globally is very aware of the study, and extremely interested in its results.
Understanding whether Vitamin D, and at what dose, is effective in preventing
MS inflammation and relapses will potentially improve healthcare for people at
risk of MS everywhere in the world”.
The PrevANZ clinical trial is examining whether vitamin D supplementation
can delay or prevent a second attack of neurological symptoms in people who
have experienced a first episode (known as a first demyelinating event or
clinically isolated syndrome) which puts them at high risk of developing MS.
While there is a great deal of evidence that low blood levels of vitamin D
are associated with an increased risk of developing MS, there is as yet no
definitive evidence that vitamin D supplementation, and at what optimal dose,
is effective to prevent the development of MS.
Australia has a critical mass of expertise in this field and MS Research
Australia has worked with researchers to develop this carefully designed trial.
The trial is funded by MS Research Australia, with the support of the state MS
Societies, including significant contributions from the MS Society of WA, MS
Queensland, Trish MS Research Foundation, Foundation 5 Million Plus and other
trusts and foundations.
The trial enrolled the first participant in June 2013, and while
recruitment has been steady, it has been a little slower than anticipated and a
number of innovative recruitment strategies are being implemented.
around Australia and New Zealand are involved in the trial and two new sites
with high recruitment potential have been established in Adelaide and the
Sydney Eye Hospital. Results are now expected in 2018.
Anyone wishing to learn more about the trial can visit www.msra.org.au/prevanz